Novel biomarkers for lupus nephritis in the "OMICS" era.

Novel biomarkers for lupus nephritis in the "OMICS" era. Curr Med Chem. 2021 Feb 11;: Authors: Dias R, Hasparyk UG, Peres ML, de Barros JLVM, Simões E Silva AC Abstract Lupus nephritis (LN) is a severe renal comorbidity associated with systemic lupus erythematosus (SLE), a complex autoimmune disorder with high morbidity and mortality. Diagnosis and monitoring of LN patients still rely on renal biopsy, a procedure that exposes patients to a variety of risks and is not capable of providing longitudinally information about disease prognosis. In this review, we summarized current data of recent promising biomarkers developed in the precision medicine era, particularly under genomic, transcriptomic, proteomic and metabolomic techniques. Genome-wide association-studies have been evaluating the role of endogenous elements beyond the autoimmunity in LN. Transcriptomic methods, including single-cell sequencing, are potential tools in identifying inflammatory signatures, miRNAs and gene expression. Proteomic measures, including anti-C1q antibodies, cytokines, TLRs, VCAM-1, NGAL osteopontin, angiostatin, have been considered helpful to provide a more profound comprehension of the disease pathogenic processes. Metabolomic approaches may identify several abnormal metabolites profiles related with the impairment of cellular functions. Together, these accurate, non-invasive and moderate-cost propedeutic resources may be the novel tools for recogni...
Source: Current Medicinal Chemistry - Category: Chemistry Authors: Tags: Curr Med Chem Source Type: research